Clinical trial outsourcing has fundamentally transformed the landscape of drug development, allowing pharmaceutical companies to streamline operations, reduce costs, and accelerate the path to market. This paradigm shift is driven by several converging factors, including the rapid growth in
The landscape of Chimeric Antigen Receptor T-cell (CAR-T) therapies is witnessing rapid evolution as emerging companies introduce innovative solutions to overcome existing challenges. These therapies, which involve genetically engineering a patient’s T cells to target cancer cells, have shown
In recent years, the intersection of advanced computing and biological research has elevated the prospects of drug discovery to unprecedented heights. The seamless integration of AI, machine learning, and supercomputing promises a paradigmatic shift from traditional empiricism to computational
Natural Killer (NK) cell therapy, once a promising beacon for cancer treatment, is now being repositioned as a potential game-changer in the management of autoimmune diseases. Biotech companies, like Artiva Biotherapeutics, are shifting their focus to explore the untapped potential of NK cell
The recent breakthrough in CAR T-cell manufacturing is nothing short of revolutionary. Researchers from the Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) at the Singapore-MIT Alliance for Research and Technology (SMART), in collaboration
In a significant achievement for GT Biopharma, Inc., the FDA has granted clearance for the company's Investigational New Drug (IND) application for GTB-3650, a novel NK cell engager aimed at treating CD33+ leukemia. This regulatory milestone allows the clinical-stage immuno-oncology company to
